IL33 and neoplasm: In conclusion, a method for enhancing in vivo immunogenic cDC1s through the direct injection of IL-33 or immunotherapy with IL-33-induced highly immunogenic Mo-DC vaccines may shed light on DC-based tumor immunotherapy.